secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Oncology Therapeutics, Inc. (BBOT)
CIK:        0001869105
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001193125-26-093997
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BBOT reports Q4 net loss $38.8M; cash runway into 2028; pipeline advances
-------------------------------------------------------------------------

- Q4 2025 net loss $38.8M (vs $19.7M in Q4 2024); full year net loss $134M (vs $74.3M).
- Cash and equivalents $425.5M; expected to fund operations into 2028.
- R&D expenses Q4 $38.1M (vs $19.5M); G&A $5.3M (vs $2.3M); increases driven by clinical and manufacturing.
- BBO-8520 monotherapy 65% ORR in KRAS G12C NSCLC; BBO-11818 first confirmed PR in PDAC; BBO-10203 no hyperglycemia.
- Clinical data readouts across all three programs expected in H2 2026; internal combinations opening later in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526093997/0001193125-26-093997-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526093997/bbot-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-093997

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer